TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...
Kitov Pharma Ltd. (“Kitov”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful ...
Georgi Kitov, who died on September 14 aged 65, led a Bulgarian archaeological team which unearthed a hoard of treasures from ancient Thrace, said to be as important as those of Agamemnon or ...
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...
Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program. The focal point of the deal is NT219, an IRS-1/2-targeting drug designed to improve the efficacy of other ...
TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...
Israel’s Kitov Pharmaceuticals Holdings is taking a majority equity stake in cancer immunotherapeutics firm TyrNovo to expand its own noncancer pipeline with TyrNovo’s preclinical-stage small-molecule ...
TEL AVIV, Israel, Dec. 15, 2015 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the ...
- Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. Following negotiations with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results